Cellular Health Screening Market Outlook 2031
The Cellular Health Screening Market size was USD 2.78 Billion in 2022 and is likely to reach USD 6.14 Billion by 2031, expanding at a CAGR of 9.2% during 2023–2031. The growth of the market is attributed to the rising adoption of telomere performance programs and rising R&D investment for cellular health projects.
Cellular health screening is a cutting-edge technique for diagnosing cellular health quickly. This test is used to figure out how a cell functions in relation to the rest of the body. Furthermore, the test can be used to track treatment progress. Cellular health screening determines the level of cellular toxicity, fat mass, intracellular and extracellular fluid, and cellular functioning.
It can be used to evaluate inflammatory illnesses like allergies, asthma, arthritis, autoimmune diseases, and inflammatory intestinal issues. With using new technology, the cellular health screening is considered to be an excellent for assessing and monitoring patients who may need to detox, shed extra body fat, or build a long-term strategy for healthy aging.
Telomere testing, oxidative stress testing, inflammation testing, and heavy metals tests are the four major tests used in cellular health screening. All these tests are risk assessment tests that can be used to determine biological age, cellular toxicity, and disease risk. Single test and multi-test panels are the two types of test kits available.
Different Biomarkers are evaluated in each test to arrive at a result. Single test panels are used to check individual biomarkers for specific outcomes, whilst multi-test panels/kits are used to evaluate a mix of biological biomarkers.
Cellular Health Screening Market Trends, Drivers, Restraints, and Opportunities
- Increasing cellular health screening applications in precision medicine as well as the increasing adoption of telomere performance programs for a healthier lifestyle are driving the market.
- Several governments’ favorable policies towards the establishment of advanced healthcare infrastructure are expected to push the market expansion.
- The market is expected to grow due to rising public awareness of cellular health screening, growing emphasis on preventive healthcare programs, and increasing incidence of genetic disorders.
- High cost of test kits, reagents, and other equipment used for cellular health screening are major challenges that are expected to restrict the market growth.
- The emergency lockdown due to a spike in COVID-19 cases affected the market as the production of cellular healthcare screening protocols have been delayed.
Scope of The Cellular Health Screening Market Report
The report on the global cellular health screening market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Cellular Health Screening Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Test Types (Single Test Panels [Telomere Tests, Oxidative Stress Tests, Inflammation Tests, and Heavy Metal Tests] and Multi-test Panels), Sample Types (Blood, Saliva, Serum, and Urine), Collection Site (Home, Office, Diagnostic Laboratories, and Hospital)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Titanovo; Telomere Diagnostics Inc.; Cell Science Systems; Life Length; Genova Diagnostics; Spectracell Laboratories; Repeat Diagnostics Inc.; Segterra, Inc.; Quest Diagnostics; Labcorp Holdings; Immundiagnostik AG; Bioreference Laboratories; Cleveland Heartlab, Inc.; Zimetry LLC: and DNA Labs India.
|
Cellular Health Screening Market Segment Insights
Multi-tests panels segment to account for a key market share
Based on the test types, the global cellular health screening market is bifurcated into single test panels and multi-test panels. The single test panels segment is further segmented into telomere tests, oxidative stress tests, inflammation tests, and heavy metal tests. The multi-tests panels segment is expected to account for a key market share during the forecast period owing to wide adoption of telomere tests due to rise in the geriatric population.
The length of telomere shortens as individuals get older and, as a result, a variety of health issues including heart disease are linked to the mentioned problem. Individuals can also check their cellular age and take protective steps to avoid telomere shortening due to the introduction of cellular health screening tests, including telomere tests.
Blood segment to dominate the market
On the basis of sample types, the market is segmented into blood, urine, saliva, and serum. The blood segment is projected to dominate the market in the coming years due to rising adoption of direct to customer approach by leading market players. In 2018, LabCorp Holdings, for example, announced the launch of a blood-testing kit that could be used at home to conduct cellular health screening tests. The firm also offers products such as a saliva-based genetic test for at-home facilities.
On the other hand, the urine segment is expected to grow during the forecasted period due to wide adoption of urine-based testing method. Use of urine as a sample for measuring and detecting oxidative stress biomarkers is both non-invasive and patient-friendly, allowing for a quick assessment of the damage caused by free oxygen radicals.
Hospital segment to hold a key market share
Based on collection sites, the global cellular health screening market is segmented into home, office, diagnostic laboratories, and hospital. The hospital segment is expected to hold a key share in the market as it provides primary care and diagnostics for the majority of the population. Diagnostic procedures for cellular health screening are usually performed in hospitals and clinics for the majority of in-patients, as doctors prescribe reliable diagnostic processes for screening and sample collection.
Meanwhile, the home segment is anticipated to grow during the forecast period. The growth is expected due to the availability of therapeutic and medical products such as rapid diagnostic tests that do not require advanced laboratory equipment or specialist preparation.
North America is to constitute a dominant share
In terms of regions, the market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is projected to constitute a dominant market share during the forecast period with a large revenue share of the global market. The market growth in this region is attributed to the rise in awareness of healthy adjusted life expectancy (HALE) and the rise in the number of people opting for cellular health screening tests.
Other factors driving the regional market growth include the increasing focus from governments on preventive measures and development of advanced healthcare facilities, massive investment in R&D programs, rising prevalence of chronic diseases, and the presence of major global players. On the other hand, the market in Asia Pacific is expected to register steady growth during the forecast period due to rise in government initiatives for development of healthcare infrastructures and growing awareness of the screening tests among patients in the region.
For example, the Government of Andhra Pradesh, India, is adopting the indicator called Happiness Index to ensure a close monitor of citizens’ health conditions. The government has taken this approach in order to persuade people to take preventative actions against various health problems.
Segments
The cellular health screening market has been segmented on the basis of
Test Types
- Single Test Panels
- Telomere Tests
- Oxidative stress Tests
- Inflammation Tests
- Heavy Metal Tests
- Multi-test Panels
Sample Types
Collection Site
- Home
- Office
- Diagnostic Laboratories
- Hospital
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Titanovo
- Telomere Diagnostics Inc.
- Cell Science Systems
- Life Length
- Genova Diagnostics
- Spectracell Laboratories
- Repeat Diagnostics Inc.
- Segterra, Inc.
- Quest Diagnostics
- Labcorp Holdings
- Immundiagnostik AG
- Bioreference Laboratories
- Cleveland Heartlab, Inc.
- Zimetry LLC
- DNA Labs India
Competitive Landscape
Some of the major players competing in the market are Titanovo; Telomere Diagnostics Inc.; Cell Science Systems; Life Length; Genova Diagnostics; Spectracell Laboratories; Repeat Diagnostics Inc.; Segterra, Inc.; Quest Diagnostics; Labcorp Holdings; Immundiagnostik AG; Bioreference Laboratories; Cleveland Heartlab, Inc.; Zimetry LLC: and DNA Labs India.
Many players are consistently working towards several market strategies such as launching new products or services, collaboration, and partnerships to achieve their targeted goals. Telomere Diagnostics Inc., for example, launched Telomere Learning Centre (TLC), a new informational platform on telomere health, in 2017. This website is intended to disseminate the most recent telomere analysis and news.
In another event, Telomere Diagnostics Inc. introduced TeloYears, a test that could measure an individual's cellular length. Strategic collaborations by market players are expected to fuel the growth of the market. For instance, in 2016, Life Length appointed Eastern Biotech & Life Sciences to launch Life Length’s telomere testing products in the GCC region.
Request For Customization
Enquiry Before Buying
Speak With Analyst
